Allergic Rhinitis Market Outlook:
Allergic Rhinitis Market size was over USD 13.08 billion in 2025 and is anticipated to cross USD 18.81 billion by 2035, witnessing more than 3.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of allergic rhinitis is estimated at USD 13.52 billion.
The allergic rhinitis industry is fostering significantly owing to the rising global incidences of allergic conditions. For instance, in April 2020, it was published in The LANCET Global Health that the cases of allergic rhinitis among children aged between 6-7 years were 11.3% and 24.4% in children aged between 13-14 years. In addition, there are rising environmental pollution, climate change, and increasing incidences of urbanization factors that raise the exposure levels to allergen agents and, therefore, to allergic rhinitis cases.
Increasing awareness of symptoms and treatment options has led to more individuals seeking to be diagnosed and treated. New pharmaceutical formulations such as novel antihistamines, intranasal corticosteroids, and biologic therapies that provide potentially better and safer profiles are responsible for fueling the market. For instance, in October 2024, GSK plc reported positive results from the phase III clinical trials ANCHOR-1 and ANCHOR-2. In this trial, depemokimab showed efficacy as well as safety in comparison to placebo in adults with CRSwNP. Furthermore, improved medical care accessibility in developing economies is also contributing to further expansion in the market.
